Therefore, our results from three murine tumor models strongly suggested that anti-Gal-9 therapy combined with ATM inhibition significantly reduces tumor growth and enhances the survival of host mice, even in poorly immunogenic tumor models that are refractory to current immune checkpoint therapy. The gene discussed is LGALS9; the disease is neoplasm.